KY
Kyntra Bio, Inc.
KYNB · NASDAQ
$7.20 +0.14% (+$0.01)
1M -9.77%
Market Cap $29.1M
P/E Ratio 0.16x
Div. Yield -
ROE -
Bulios Fair Price
$7.92
10.0% upside
Current Price
$7.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KYNB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
74 /100
Cheap P/E 0.16x
P/S 6.31x
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 64.23%
EPS growth N/A
Book val. growth N/A
Profitability
25 /100
Weak Gross margin 18.15%
FCF margin 824.39%
Net margin 3,967.77%
Quality
22 /100
Poor ROIC 78.16%
Asset turnover 0.05x
ROA 181.24%
Debt
43 /100
Moderate Current ratio 2.69x
Int. coverage -10.14x
Debt/Equity N/A
Stability
39 /100
Moderate Beta 1.06x
Profitable years 1
Rev. volatility 21.45%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KYNB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Thane Wettig
Employees
34
Headquarters
San Francisco
Upcoming events
09 NOV
Earnings
Upcoming earnings report